Pain is the most common symptom of bone cancer. TGF-␤, a major bone-derived growth factor, is largely released by osteoclast bone resorption during the progression of bone cancer and contributes to proliferation, angiogenesis, immunosuppression, invasion, and metastasis. Here, we further show that TGF-␤1 is critical for bone cancer-induced pain sensitization. We found that, after the progression of bone cancer, TGF-␤1 was highly expressed in tumor-bearing bone, and the expression of its receptors, TGF␤RI and TGF␤RII, was significantly increased in the DRG in a rat model of bone cancer pain that is based on intratibia 
Introduction
Bone cancer pain is one of the most severe types of chronic pain. Abnormal activity in primary sensory neurons is implicated in this pain process. Tumor-derived products have been shown to sensitize and injure primary sensory neurons (Hamamoto et al., 2008) . Thus, successful treatment of bone cancer pain will need to address the abnormal sensitization of peripheral nociceptors.
TGF-␤ is a major bone-derived growth factor that is secreted in a latent form by bone cells and stored in the bone matrix (Dallas et al., 2002) . Numerous studies have shown the importance of TGF-␤ for the development of bone metastases. In advanced bone cancer, excessive levels of TGF-␤ promote tumor growth, invasion, and metastasis (Massagué, 2008) . Tumors in bone secrete a multitude of factors, including osteoblastic factors and osteolytic factors. TGF-␤ is released and activated from the mineralized bone matrix by osteoclastic bone resorption and further induces the production of osteolytic factors by tumors. The reciprocal interaction between cancer cells and the bone microenvironment drives a feedforward cycle that increases both tumor growth and bone destruction (Mundy, 2002; Juárez and Guise, 2011) . Blocking TGF-␤ to interrupt this vicious cycle between cancer and bone has been considered a promising strategy for the treatment of bone metastasis. Preclinical studies show that TGF-␤ inhibitors are effective at treating and preventing tumor cell invasiveness and bone metastases as well as at increasing bone mass (Bandyopadhyay et al., 2006; Juárez and Guise, 2011) . In this study, we further investigated whether and how TGF-␤ in the periphery regulates metastatic bone cancer-evoked hyperalgesia in a rat model of bone cancer pain induced by intratibia inoculation of Walker 256 mammary gland carcinoma cells.
A recent report indicates that TGF-␤ is involved in inflammatory pain signaling by increasing Cdk5-dependent transient receptor potential vanilloid 1 (TRPV1) phosphorylation (Utreras et al., 2012) . TRPV1 is a nonselective cation channel that is expressed by nociceptors and can be activated by noxious heat (Ͼ43°C), extracellular protons, various lipids, and capsaicin (Caterina et al., 1997) . TRPV1 expression increased in the DRG after cancer infiltration and contributed to thermal hyperalgesia (Niiyama et al., 2007; Pan et al., 2010; Han et al., 2012) . Selective blockade of TRPV1 results in a significant attenuation of nociceptive behaviors in bone cancer pain models (Ghilardi et al., 2005; Niiyama et al., 2009; Kawamata et al., 2010) . Therefore, in the present study, we used in vitro and in vivo approaches to study the role of TGF-␤1 in bone cancer pain by sensitizing TRPV1. Our results indicate that TGF-␤1 released from tumor-inoculated bone tissue may increase the excitability of DRG neurons by sensitizing TRPV1 via the TGF-␤ activating kinase 1 (TAK1)/p38 MAPK and PKC signaling pathways, leading to hyperalgesia in animals with bone cancer.
Materials and Methods
Animals. Female Wistar rats weighing 150 -180 g were obtained from the Shanghai Experimental Animal Center of the Chinese Academy of Sciences and were housed under a 12:12 light-dark cycle with food and water ad libitum. Knock-out mice lacking Trpv1 (Trpv1 Ϫ/Ϫ ) and C57BL/6 background WT control mice (both sexes, 8 -10 weeks) were purchased from The Jackson Laboratory and bred in the Animal Center of Fudan University. All animal experiments were approved by the Shanghai Animal Care and Use Committee and followed the policies issued by the International Association for the Study of Pain on the use of laboratory animal (Zimmermann, 1983) . All the following behavioral testing, quantification of Western blot, and immunohistochemical experiments described herein were performed by experimenters that were blind with respect to the treatments.
Model of bone cancer pain. Tumor cells were extracted from ascetic fluid of rats that were administered Walker 256 rat mammary gland carcinoma cells. Suspensions of 1 ϫ 10 8 /ml tumor cells in PBS were prepared. The surgery was conducted as previously described (Duan et al., 2012) . Briefly, rats were anesthetized with sodium pentobarbital (50 mg/kg i.p.). The right leg was shaved, and the skin was disinfected with iodine tincture and 75% ethanol. Superficial incisions were made in the skin overlying the patella. A 23-gauge needle was inserted at the site of the intercondylar eminence of the tibia and was then replaced with a 10 l microinjection syringe containing a 4 l suspension of tumor cells. The contents of the syringe were slowly injected into the right tibia cavity. To prevent leakage of cells outside the bone, the injection site was sealed with bone wax. Then, the skin wound was closed. For the sham group (control), 4 l of PBS was injected instead of carcinoma cells into the tibia. At the end of the experiment, radiological, postmortem, and histological evaluations were performed. Rats that showed no obvious tumor growth and bone destruction after inoculation of tumor cells were excluded from the experiments.
Drugs and administration. TGF-␤1 was purchased from Peprotech and was dissolved in a citrate buffer (50 g/ml) and then diluted in sterile 0.01 M PBS with 2 mg/ml BSA at 5 g/ml to create a stock solution. The TGF␤RI kinase inhibitor SD-208, the ERK MAPK inhibitors PD98059 and U0126, the PKC inhibitor bisindolylmaleimide VII (BIM), capsaicin, and the TRPV1 receptor inhibitor capsazepine were purchased from Sigma. The p38 MAPK inhibitor SB203580 and the JNK MAPK inhibitor SP600125 were purchased from Merck KGaA. The TAK1 inhibitor (5Z)-7-oxozeaenol was purchased from Tocris Bioscience. The drugs were dissolved in DMSO or normal saline as stock solutions. All of the stock solutions were stored at Ϫ20°C or Ϫ80°C until use. Working concentrations of the drugs were prepared on the day of the experiment from the stock solutions. The drug dosages were selected based on previous reports and our preliminary studies. In the whole-cell patch-clamp recordings, TGF-␤1 (10 ng/ml) was applied continuously for 20 min, capsaicin challenges (1 M) were applied for 3 s and TRPV1 currents were recorded. The inhibitors were applied to the chamber 30 min before and during the TGF-␤1 perfusion. In the calcium imaging experiments, capsaicin (1 M) was administered 5 times, with a 90 s interval between trials. TGF-␤1 (10 ng/ml) was perfused 20 min before and during the capsaicin challenges. SD-208 was applied 15 min before and during the TGF-␤1 perfusion. In the behavioral experiments, SD-208 was delivered into local deep tissue around the tumor bone or the spinal space via a lumbar puncture performed with a 30-gauge needle between the L5 and L6 vertebrae (Duan et al., 2012) . Capsazepine, SB203580, and BIM were delivered via intraplantar injection 20 min before TGF-␤1 (intraplantar).
Preparation of DRG neurons. Rats were anesthetized with isoflurane and then rapidly decapitated. The DRGs from spinal L3-L5 segments were removed and immediately transferred onto DMEM (Invitrogen ) on ice. The ganglia were minced with fine spring scissors and treated with collagenase (type IA, 2.67 mg/ml, Sigma) and trypsin (type I, 1 mg/ml, Sigma) in DMEM at 37°C for 35 min. After washing with a standard external solution, the ganglia were then gently triturated using fine firepolished Pasteur pipettes. The isolated DRG neurons were plated onto glass coverslips in 3.5 cm culture dishes and incubated with a standard external solution containing (in mM) as follows: 150 NaCl, 5 KCl, 2.5 CaCl 2 , 1 MgCl 2 , 10 HEPES, and 10 glucose, pH 7.4, at room temperature for Ͼ2 h.
Patch-clamp recordings. Whole-cell patch-clamp recordings of DRG neurons were performed at room temperature (23 Ϯ 1°C) using an Axonpatch 200B amplifier (Molecular Devices). All of the recordings were performed in small-diameter (15-25 m) DRG neurons and were made 2-8 h after plating, with resting membrane potentials more negative than Ϫ50 mV. Microelectrodes (N51A borosilicate glass, Sutter Instruments) with a resistance of 2-6 M⍀ were pulled using a P97 puller (Sutter Instruments). The pipette solution contained (in mM) as follows: 140 KCl, 1 MgCl 2 , 0.5 CaCl 2 , 5 EGTA, 3 Na 2 ATP, 0.2 NaGTP, and 10 HEPES, pH 7.2. Seals (1-10 G⍀) between the electrode and the cells were established. After the whole-cell configuration was established, the cell membrane capacitance and series resistance were compensated (Ͼ80%). Leak currents were subtracted using the online P/4 protocol. The data were sampled at 10 kHz and low-passed at 2 kHz. Capsaicin-induced TRPV1 currents were recorded in voltage-clamp mode, with the membrane potential held at Ϫ70 mV. Action potentials were elicited by injecting a depolarizing current (50 pA, 400 ms). Drugs were applied using a DVD-8VC superfusion application system (ALA Scientific Instruments). The perfusion tube (inner diameter, 100 m) was located ϳ200 m from the recorded cell, with a rapid solution exchange of 20 ms. Only one recording was performed on each dish to ensure that data were not obtained from cells that had been inadvertently exposed to other test treatments. Two or three cells were studies per animal to ensure the data from different animals. Data acquisition and analysis were performed with Clampfit 10.2 (Molecular Devices) and/or Origin 7.5 (Microcal Software) software.
Calcium imaging. The acutely isolated DRG neurons were loaded with 1 M fura-2 AM (DoJinDo Laboratories) for 1 h and were then washed and incubated with standard external solution. The entire process was protected from light. The neurons were observed on an inverted microscope (Olympus IX51) with a 40ϫ UV flour oilimmersion objective lens. The fluorescence of the individual neurons was recorded by a cooled CCD camera (Hamamatsu), with a 1 Hz alternating wavelength, time scanning with excitation wavelengths of 340 and 380 nm and an emission wavelength of 510 nm (monochromators; Till Polychrome IV). Images were captured every 1.5 s. Digitized images were acquired and analyzed by SimplePCI (Compix). The ratio of the fluorescence at the two excitation wavelengths was represented to estimate the changes in the [Ca 2ϩ ]i. Behavioral tests. Animals were habituated to the testing environment daily for at least 3 d before baseline testing. Thermal hyperalgesia was assessed by measuring the paw withdrawal latency latencies (PWLs) in response to a radiant heat source. Animals were placed individually into Plexiglas chambers on an elevated glass platform and allowed to acclimate for 30 min. A radiant heat source (IITC/Life Science Instruments) was applied from underneath the platform to the glabrous surface of the paw through the glass plate. The heat source was turned off when the animal lifted its foot, allowing for measurement of the time from the onset of radiant heat application to the withdrawal of the hindpaw. This time was defined as the PWL. The heat was maintained at a constant intensity, which produced a stable PWL of 10 -12 s in naive animals. A 20 s cutoff was used to prevent tissue damage in the absence of a response.
Bone radiological detection. Rats were placed on a clear Plexiglas plane and exposed to an x-ray source under sodium pentobarbital anesthesia. Using the Digital Radiographer System (Philips, BV Pulsera C-arm), radiographs were taken from both hind limbs of naive, sham, and bone cancer rats.
Bone histology. Rats were anesthetized with an overdose of urethane (1.5 g/kg, i.p.) and transcardially perfused with 300 ml of 0.9% normal saline followed by 300 ml of 4% paraformaldehyde. Bilateral tibia bones were removed and decalcified in decalcifying solution for 24 h. The bones were rinsed and dehydrated and then embedded in paraffin, cut into 7 m cross sections using a rotary microtome (Reichert-Jung 820, Cambridge Instruments), and stained with hematoxylin and eosin to visualize the extent of tumor infiltration and bone destruction.
Immunohistochemistry/immunocytochemistry. Animals were given an overdose of urethane and were then transcardially perfused with normal saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4, 4°C). DRGs (L3-L5 segments) were removed and postfixed in the same fixative for 2 h at 4°C and then immersed in a 10 -30% gradient of sucrose in phosphate buffer for 24 -48 h at 4°C for cryoprotection. DRG sections (15 m) were cut on with a cryostat (Leica 1900, Leica) and mounted onto gelatin-coated slides for immunofluorescence. Control and treated DRG sections were mounted on the same slides and processed under the same conditions.
The slides were blocked after blocking with 10% donkey serum in 0.01 M PBS, pH 7.4, with and 0.3% Triton X-100 for 2 h at room temperature and incubated for 36 h at 4°C; the slides were incubated with goat anti-TRPV1 (1:200; Santa Cruz Biotechnology) primary antibody in PBS with 1% normal donkey serum and 0.3% Triton X-100 for 36 h at 4°C. After three 15 min rinses in PBS, the slides were incubated followed by incubation within rhodamine red-X-conjugated donkey anti-goat IgG (1:200; Jackson ImmunoResearch Laboratories) for 2 h at room temperature. For TRPV1/TGF␤RI /TGF␤RII or TRPV1/ CGRP/NF-200 double immunofluorescence, the slides were incubated in a mixture of goat anti-TRPV1 (1:200) and rabbit anti-TGF␤RI (1:200, Santa Cruz Biotechnology), rabbit anti-TGF␤RII (1:200, Santa Cruz Biotechnology), mouse anti-CGRP (calcitonin gene-related peptide, a marker for peptide-containing DRG neurons, 1:3000, Sigma), or mouse anti-NF-200 (a marker for DRG neurons with myelinated fibers, 1:3000, Sigma) primary antibodies for 36 h at 4°C. The slides were then incubated with a mixture of rhodamine red-X-conjugated donkey anti-goat IgG (1:200) and FITC-conjugated donkey anti-rabbit IgG (1:200; Jackson ImmunoResearch Laboratories) secondary antibodies for 2 h at room temperature. All of the slides were coverslipped with 50% glycerin in 0.01 M PBS and then examined with an Olympus FV1000 confocal laser scanning microscope (Olympus). Images were acquired using FV10-ASW software. For the quantification of the immunoreactive signals, every 20th section was picked from a series of consecutive DRG sections, and four sections were counted for each DRG. The numbers of immunopositive cells were expressed as percentages of the total neuronal profiles in the same section. The specificities of the immunostaining were verified by observing no immunostaining after omitting the primary antibodies, which resulted in the disappearance of the immunostaining signals. The specificities of the primary antibodies were verified by a preabsorption experiment. Sections were first incubated overnight with a mixture of TRPV1, TGF␤RI, or TGF␤RII primary antibody and the corresponding blocking peptide (5:1 blocking peptide: primary antibody), followed by incubation with a secondary antibody. The immunostaining signals were abolished after absorption.
For PKC visualization, DRG neurons on coverslips were treated with TGF-␤1 (10 ng/ml) or the TFG␤RI antagonist SD-208 (1 M).
TGF-␤1 was added for 30 min. SD-208 was added 30 min before TGF-␤1. Negative controls were treated alike but without the addition of any pharmaceutical reagents. The DRG neurons were rapidly fixed with 4% paraformaldehyde for 10 min at room temperature. After blocking with 10% donkey serum and 0.3% Triton X-100 for 1 h, the neurons were incubated overnight at 4°C with rabbit antipPKC Ser729 (1:200, Santa Cruz Biotechnology) and goat anti-TRPV1 (1:200,Santa Cruz Biotechnology). The cultured neurons were then incubated for 1 h at room temperature with FITCconjugated donkey anti-rabbit IgG and rhodamine red-X-conjugated donkey anti-goat IgG. To quantify PKC translocation, 100 randomly selected cells were evaluated in each optic field. All counting was performed by the same observer, who was blinded to the experimental groups. All treatments were repeated with DRG neurons from four rats. The criteria for determining PKC membrane translocation were based on previous reports (Cesare et al., 1999; Zhu et al., 2007) . Briefly, a 25 m line was drawn across the cell body to measure the florescence intensity along the line. If the intensity for a particular cell was higher in the cytoplasm than in the membrane, the cell was designated Ϫ1. Conversely, if the intensity in the distal membrane of a cell was high with two peak values, the cell was designated ϩ1.
Western blots. The L3-L5 DRGs and tibia (near the metaphysic) from bone cancer and control rats were collected and then homogenized in the lysis buffer (12.5 l/mg tissue) containing a mixture of protease inhibitors (Roche) and PMSF (Sigma). The protein concentrations of the lysate were measured using a BCA Protein Assay kit (Pierce Biotechnology). Equal amounts of protein samples were loaded and separated in 10% SDS-PAGE gel and then transferred to PVDF membranes (Millipore). After 2 h, the membranes were blocked in blocking with 5% nonfat dry milk for 2 h at room temperature, and membranes were incubated overnight at 4°C with rabbit anti-TGF-␤1 (1:1000, Sigma), rabbit anti-TGF␤RI (1:1000, Santa Cruz Biotechnology), rabbit anti-TGF␤RII (1: 1000, Santa Cruz Biotechnology), or rabbit anti-p-p38 (1:500, Cell Signaling Technology) primary antibodies. The blots were then incubated with the secondary antibody, followed by HRP-conjugated goat anti-rabbit IgG conjugated with HRP secondary antibody (1:3000, Santa Cruz Biotechnology) for 2 h at room temperature. The blots were probed with GAPDH antibody as a loading control. Signals were finally detected using enhanced chemiluminescence (Pierce), and the bands were visualized with the ChemiDoc XRs system (Bio-Rad). All Western blot analysis was performed at least 3 times, and consistent results were obtained. Bio-Rad Image Analysis System was then used to measure the integrated optic density of the bands.
Statistical analysis. The data are presented as the mean Ϯ SEM. Student's t tests (for comparisons of two groups) or one-way ANOVAs (or two-way ANOVA, for multiple group comparisons) followed by post hoc Student-Newmann-Keuls tests were used to identify significant differences. In all cases, p Ͻ 0.05 was considered statistically significant.
Results

TGF-␤1 and TGF␤Rs are involved in bone cancer pain
After intratibia inoculation with Walker 256 mammary gland carcinoma cells, thermal hyperalgesia developed within days 6 -8, peaked at day 14, and persisted for at least 20 d in the ipsilateral hindpaw (two-way ANOVA, treatment: F (1,13) ϭ 46.308, p Ͻ 0.001; treatment ϫ time: F (10,117) ϭ 2.466, p ϭ 0.009) (Fig. 1A) . Thus, in this study, we selected day 14 post-tumor inoculation to perform the following experiments. The radiographs showed signs of radiolucent lesions in the tibia close to the injection site, especially at the proximal epiphysis, on post-tumor day 14 (PTD 14) (Fig. 1B) . The postmortem evaluation showed robust tumor growth in the ipsilateral but not in the contralateral tibia (Fig. 1C) or other bones (data not shown). The hematoxylin and eosin-stained tibia sections showed both tumor growth and bone destruction with medullary bone loss on PTD 14 (Fig. 1D) .
Tumor growth and bone destruction lead to the production of TGF-␤ (Mundy, 2002; Juárez and Guise, 2011) . We therefore examined TGF-␤1 expression in tumor-bearing bone. As shown in Figure  1E , the level of TGF-␤1 protein robustly increased in the advanced cancer rats (one-way ANOVA, F (3,9) ϭ 9.656, p ϭ 0.006).
TGF-␤ mediates its biological effect through TGF-␤ receptor type I (TGF␤RI) and the TGF␤RII transmembrane serine/ threonine receptor (Derynck and Zhang, 2003) . We measured TGF␤RI and TGF␤RII protein levels in L3-L5 DRGs ipsilateral to the affected bone in cancer rats. Western blot analysis showed that there was significant upregulation of both TGF␤RI and TGF␤RII on PTD 14 (oneway ANOVA, TGF␤RI: F (2,21) ϭ 6.95, p ϭ 0.005; TGF␤RII: F (2,21) ϭ 11.461, p Ͻ 0.001) (Fig. 1 F, G) .
To address whether TGF␤Rs are involved in bone cancer-induced thermal hyperalgesia, we observed the effects of local injection (around tumor bone) of the TFG␤R antagonist, SD-208, in the PTD14 rats. When SD-208 (2.5 mg/kg) was injected into deep tissue around tumor bone, bone cancerinduced thermal hyperalgesia was significantly inhibited (twoway ANOVA, treatment: F (1,16) ϭ 9.157, p Ͻ 0.001) (Fig. 1H ) . Consistently, the hyperalgesia was also suppressed by lumbar puncture (LP) injection of SD-208 (1 or 5 g/20 l) (Fig. 1I ) . It has been reported that drugs can be predominantly delivered into DRG neurons by direct lumbar puncture (Vulchanova et al., 2010; Duan et al., 2012) . LP injection of SD-208 (5 g/20 l) had no effect on PWL in naive rats (Fig. 1J ) .
TGF-␤ mediates bone cancer pain by sensitization of TRPV1
The tumor-induced osteoclastic process results in TGF-␤ activation and local environment acidification (Griffiths, 1991) , which can activate TRPV1 at normal body temperatures (Tominaga et al., 1998) . Therefore, we examined TRPV1 expression and colocalization with TGF-␤Rs in primary sensory neurons. A significant increase in the number of TRPV1-positive neurons was consistently detected in L3-L5 DRGs ipsilateral to the tumor- inoculated bone on PTD 14 (Fig. 2A) . Double immunofluorescence revealed that TRPV1 was predominantly expressed in isolectin B4 (IB4)-positive and CGRPpositive DRG neurons. At PTD 14, TRPV1-positive signals were significantly increased in both IB4-and CGRP-positive neurons. Few NF-200-positive neurons were TRPV1-positive in both the sham and bone cancer rats (Fig. 2B) . Moreover, we observed that either TGF␤RI or TGF␤RII was heavily colocalized with TRPV1 in the DRG neurons; ϳ90% TRPV1-positive neurons expressed TGF ␤RI or TGF␤RII (Fig. 3A) . To address whether increased peripheral TGF-␤1 is involved in the bone cancer-induced upregulation of TRPV1 and TGF-␤Rs in the DRG, we examined the effects of directly intraplantar TGF-␤1 on TRPV1 and TGF␤RI levels in the L3-L5 DRGs. As shown in Figure 3B , a robust increase in either TRPV1-or TGF␤RI-positive neurons was detected at 4 and 24 h after intraplantar injection of TGF-␤1 (250 ng/50 l). These results provided morphological evidence for the functional interaction between TGF␤ and TRPV1.
Given that TRPV1 was predominantly expressed in small-diameter IB4-positive and CGRP-positive DRG neurons, wholecell patch recordings were performed in acutely isolated small-diameter (Ͻ25 m) DRG neurons. Consistent with our previous studies , capsaicin (0.5-5 M) induced an inward current in a dose-dependent manner in ϳ70% of the recorded neurons (Fig.  4 A, B) . After bone cancer development, the percentage of DRG neurons that were responsive to capsaicin was increased to Ͼ90%, and the dose-response curve of capsaicin currents was left-shifted on PTD 14 (Fig. 4B ). Successive applications of 1 M capsaicin (3 s, interval of 60 s) produced a progressive decline or desensitization in the responses in the neurons from both normal and bone cancer rats (Fig. 4C,D) . The amplitude of the TRPV1 currents was much greater, and the rate of desensitization was much less in DRG neurons from PTD 14 rats than those from control rats (Fig.  4C-F ) .
Next, we examined whether peripheral TGF-␤ can directly produce thermal hyperalgesia. As shown in Figure 5A , intraplantar injection of TGF-␤1 (250 ng/50 l) produced a robust thermal hyperalgesia in naive rats. Interestingly, this TGF-␤1-induced hyperalgesia was completely abolished by the TRPV1 antagonist, capsazepine (1.5 g/50 l) (Fig. 5A) . A two-way ANOVA revealed significant differences in the treatment groups (F (3,28) ϭ 26.796, p Ͻ 0.001) and in the interaction between the treatment and time (F (24,224) ϭ 2.531, p ϭ 0.002). This result was further confirmed in Trpv1 knock-out mice.
The TGF-␤1 (intraplantar 25 ng/5 l)-induced thermal hyperalgesia was observed only in wild-type (C57BL/6) mice and not in Trpv1 Ϫ/Ϫ mice (Fig. 5B) . Consistent with the behavioral hypersensitivity, whole-cell current-clamp recordings showed that TGF-␤1 (10 ng/ml) greatly increased the action potential firing frequencies of small-diameter DRG neurons (paired t test, t (0.05,6.357) , p Ͻ 0.001) (Fig. 5C,D) .
To determine the effects of TGF-␤1 on TRPV1 activity, 1 M capsaicin-induced TRPV1 currents were recorded in the presence of TGF-␤1 (10 ng/ml). As shown in Figure 5 , E and F, TGF-␤1 progressively potentiated TRPV1 currents during a 20 min perfusion in small-diameter DRG neurons. Pretreat- ment with SD-208 (1 M), a selective TFG␤RI antagonist, for 30 min prevented the TGF-␤1-induced potentiation of TRPV1 currents completely. Analogously, the repetitive capsaicininduced desensitization in the responses of [Ca 2ϩ ] i increases by capsaicin was also antagonized by exogenous TGF-␤1. This effect was abolished by the TFG␤RI antagonist SD-208 (Fig.  5G,H ) .
TGF-␤1-induced sensitization of TRPV1 is mediated by
Smad-independent PKC and TAK1/p38 TGF-␤ can alter cell behavior through the activation of Smaddependent and Smad-independent pathways. To address whether the Smad-dependent pathway is involved in TRPV1 sensitization, the Smad3 inhibitor SIS3 was used to block the phosphorylation of Smad3 and the interaction of Smad3 with Smad4. As shown in Figure 6 , the TGF-␤1-induced potentiation of TRPV1 currents was not blocked by SIS3 (10 M).
Several non-Smad-signaling pathways have been linked to the TGF␤RI/TGF␤RII complex. PKC has been reported to be activated by a wide variety of growth factors, including TGF-␤ 1 (Mulsow et al., 2005; Nagaraj and Datta, 2010) , and is strongly implicated in TRPV1 sensitization (Numazaki et al., 2002; Bhave et al., 2003; . We therefore assessed whether PKC is involved in the sensitization of TRPV1 by TGF-␤1 in small DRG neurons. Although the PKC inhibitor BIM (1 M) did not affect TRPV1 currents per se, it completely abrogated the TGF-␤1-induced enhancement of TRPV1 currents (Fig. 6 A, B) .
Several PKC isoforms (␦, ␤⌱, ␤⌱⌱, , and ) are present in rat DRG neurons (Cesare et al., 1999) . Among the different PKC isoforms, PKC is coexpressed with TRPV1 in DRG neurons and is phosphorylated after inflammation (Zhou et al., 2003) . Translocation of PKC to the cell membrane triggers TRPV1 phosphorylation and sensitization (Numazaki et al., 2002) . Our results showed that the addition of PKC translocation inhibitor peptide (200 M) to the recording pipette completely abolished the TGF-␤-induced TRPV1 sensitization (Fig. 6 A, B) . TGF-␤ also caused a significant translocation of PKC immunoreactivity to the plasma membrane in DRG neurons, especially in TRPV1-positive neurons (Fig. 6C,D) . Preincubation with the TFG␤RI antagonist SD-208 (1 M) for 30 min greatly diminished TGF-␤-induced translocation (one-way ANOVA, F (3, 20) ϭ 21.838, p Ͻ 0.001) (Fig. 6C,D) . Moreover, behavioral testing showed that an intraplantar injection of the PKC inhibitor BIM (0.5 g) blocked peripheral TGF-␤1-induced thermal hyperalgesia. BIM (0.5 g/50 l) per se did not change basal PWL in response to noxious heat stimulation (Fig. 6E) .
TGF-␤ can also elicit cellular responses through TAK1, a member of the MAPKKK family. TAK1 is involved in the activation of several MAP kinases (MAPK), including ERK, p38, and JNK (Massagué, 2008; Nagaraj and Datta, 2010; Mu et al., 2012) . Thus, we investigated the role of the TAK1-MAPK pathways in the TGF-␤1-induced sensitization of TRPV1. As shown in Figure 7 , TGF-␤1-induced potentiation of TRPV1 currents was completely blocked by the TAK1 inhibitor (5Z)-7-oxozeaenol (1 M). Furthermore, blockade of p38 activation by SB203580 (10 M) also abolished TGF-␤1-induced TRPV1 sensitization. In contrast, neither the JNK inhibitor SP600125 (10 M) nor the MEK (upstream of ERK1/2) inhibitors PD98059 (10 M) and U0126 (5 M) prevented the TGF-␤1-induced sensitization of TRPV1 (Fig. 7 A, B) . Accordingly, an intraplantar injection of TGF-␤1 induced behavioral hypersensitivity, which was blocked by a preinjection of the p38 inhibitor SB203580 (10 g) (Fig. 7C) .
The involvement of p38 in bone cancer pain was further confirmed. Western blot analysis showed that there was significant upregulation of p-p38 level in affected DRGs on PTD 14 (oneway ANOVA, F (2,12) ϭ 40.99, p Ͻ 0.001) (Fig. 7D) . On PTD 14 when the thermal hyperalgesia was steadily developed, LP injection of the p38 inhibitor, SB203580 (10 g/20 l), significantly reversed existing thermal hyperalgesia in the hindpaw that was ipsilateral to the affected bone (Fig. 7E ).
Discussion
The TGF-␤ superfamily includes activins, BMPs, growth and differentiation factors, and TGF-␤s (Lantero et al., 2012) . The TGF-␤s family contains three related mammalian isoforms: TGF-␤1, TGF-␤2, and TGF-␤3 (Janssens et al., 2005) . All three isoforms are detected in bone, but the most abundant in bone is TGF-␤1 (Hering et al., 2001) . It has been shown that increased expression of TGF-␤1 is often correlated with the aggressiveness and grade/stage of a tumor, as well as a high incidence of metastasis (Muraoka et al., 2002; Massagué, 2008) . Blocking TGF-␤1 or its signaling inhibits tumor cell invasiveness in vitro and metastatic ability in vivo (Ananth et al., 1999; Rowland-Goldsmith et al., 2002) . A recent study demonstrated that, in bone metastases mice, the osteolytic lesions were significantly decreased after 4 weeks of treatment with the TGF␤R-I inhibitor, SD-208 (Mohammad et al., 2011) . In the present study, we further showed that excessive levels of TGF-␤1 in advanced-stage bone tumors also contributed to bone cancer pain. Thus, TGF-␤1 and its signaling effectors and modulators may be promising molecular targets of novel therapeutic agents for both the treatment of bone metastases and the management of bone cancer pain.
TGF-␤1 contributes to bone cancer-induced thermal hyperalgesia
The most common symptom of bone cancer is pain. The severity of the pain is closely correlated with the extent of bone destruction (Adami, 1997) . TGF-␤, which plays a prominent role in breast cancer progression and bone metastasis, is a central mediator that drives a feedforward cycle of tumor growth in bone (Mundy, 2002; Juárez and Guise, 2011) . Correspondingly, in a rat model of bone cancer, we found that TGF-␤1 was highly expressed in the tumor-inoculated bone and that this increased expression was associated with tumor growth and bone destruction. A concomitant increase in the expression of its receptors, TGF␤RI and TGF␤RII, in the DRG and robust thermal hyperalgesia in the affected hindpaw were observed. In particular, the TGF␤RI antagonist, SD-208, significantly suppressed bone cancer-induced thermal hyperalgesia, indicating a role for TGF-␤1 in bone cancer pain.
TGF-␤ has been implicated in pain signaling, but its precise role is not completely clear. For instance, Echeverry et al. (2009) showed that TGF-␤1 was implicated in the negative modulation of neuropathic pain through neuroprotective effects, inhibiting the activation of spinal microglia and astrocytes. Studies from the Hurle group using BMP and activin membrane-bound inhibitor (BAMBI)-KO mice (Bambi Ϫ/Ϫ mice) implicated the TGF-␤ superfamily members in the modulation of chronic and acute pain perception through the transcriptional regulation of genes that encode endogenous opioids (Tramullas et al., 2010; Lantero et al., 2012) . In contrast, activin A, another member of the TGF-␤ superfamily, was reported to cause acute thermal hyperalgesia by sensitizing peripheral TRPV1 (Zhu et al., 2007) and increasing the expression in DRG neurons of CGRP, a peptide marker of the major subset of peripheral nociceptors that contribute to the development of hyperalgesia in pathological pain ; TGF-␤1 and TGF-␤2 increased the levels of substance P (SP) (Lantero et al., 2012), which can sensitize TRPV1 and produce thermal hyperalgesia via the NK-1 receptor (Zhang et al., 2007). TGF-␤ superfamily members, BMP2, BMP4, BMP6, and BMP7, also induce a strong increase in the expression of CGRP and SP in cultured embryonic DRG neurons (Ai et al., 1999) . A recent study also showed that a deficiency in TGF-␤ signaling in Tgfb1 Ϫ/Ϫ mice, or mice in which the transforming growth factor-␤ receptor 1 (Tgfbr1) is conditionally knocked out in the trigeminal ganglia and DRG, resulted in reduced Cdk5 activity and attenuated thermal hyperalgesia after peripheral inflammation, suggesting a positive role for TGF-␤1 in inflammation-induced hyperalgesia (Utreras et al., 2012) . In support of this finding, we observed in the present study that an intraplantar injection of TGF-␤1 induced immediate thermal hyperalgesia. Thus, TGF-␤1 may positively modulate sensitivity of nociceptive primary afferent neurons in peripheral inflammation and bone cancer pain.
TGF-␤1 is involved in bone cancer-induced thermal hyperalgesia by sensitizing TRPV1
Previous studies revealed that, after cancer infiltration, TRPV1 expression increased in the DRG and contributed to thermal hyperalgesia (Niiyama et al., 2007; Pan et al., 2010; Han et al., 2012) . Selective blockade of TRPV1 resulted in a significant attenuation of nociceptive behavior in various models of cancer pain (Ghilardi et al., 2005; Niiyama et al., 2007) . Consistently, in the present study, we observed a significant upregulation in TRPV1 expression in the DRG on PTD 14 in bone cancer rats. In addition to an increase in TRPV1 expression, enhanced TRPV1 currents and a decreased desensitization rate to repetitive capsaicin application were also observed in DRG neurons from PTD 14 bone cancer rats. These results suggest that both transcriptional changes in TRPV1 expression and post-translational changes in the sensitivity of the TRPV1 channel may be involved in bone cancer-induced thermal hyperalgesia.
TRPV1 is present on sensory fibers in mineralized bone and bone marrow (Ghilardi et al., 2005) . There are at least two mechanisms in bone cancer that may contribute to the sensitization of TRPV1. One such mechanism is involved in the sensitivity of TRPV1 to acid. Osteoclast-mediated acidosis and lysis of acidic tumor cells result in an acidic environment (Griffiths, 1991; Boyle et al., 2003) , which can, at normal body temperatures, activate TRPV1 on the primary afferent fibers that innervate the affected bone (Tominaga et al., 1998) . Another possible mechanism is sensitization of TRPV1 by chemical mediators, including bradykinin, SP, ATP, NGF, and activin (Woolf and Salter, 2000; Zhu et al., 2007) . We have now shown that TGF-␤1 can also sensitize TRPV1 within 20 min of its application, consistent with its abilities to increase the action potential firing frequencies of small DRG neurons and induce thermal hyperalgesia after intraplantar injection. Furthermore, TGF-␤1-induced thermal hyperalgesia can be abolished by the TRPV1 antagonist capsazepine; in addition, TGF-␤1-induced thermal hyperalgesia only occurred in widetype, but not in TRPV1 Ϫ/Ϫ mice, suggesting that the sensitization of TRPV1 is necessary for TGF-␤1-induced thermal hyperalgesia. In addition to increasing the sensitivity of TRPV1, TGF-␤1 was also shown to upregulate TRPV1 expression and antagonize TRPV1 desensitization in DRG neurons. It is plausible that excessive levels of TGF-␤1 in bone tumors contribute to bone cancer-induced thermal hyperalgesia via increasing the sensitivity and expression density of TRPV1.
TGF-␤1 sensitization of TRPV1 by TGF-␤R-mediated PKC and TAK/p38 signaling pathways Bioactive TGF-␤ binds with high affinity and selectivity to TGF␤RII, which then recruits and activates TGF␤RI, enabling the subsequent phosphorylation of downstream substrates (de Caestecker, 2004; Krieglstein et al., 2011) . The TGF-␤1 receptor subunits TGF␤RI and TGF␤RII are present in DRG neurons, and both types of receptors are coexpressed with TRPV1. After the development of bone cancer pain, TGF␤RI and TGF␤RII levels were significantly increased in the affected DRG on PTD 14. The TGF-␤1-induced sensitization of TRPV1 and bone cancerinduced thermal hyperalgesia were blocked by the TGF␤RI kinase inhibitor SD-208, suggesting that this receptor kinase is required for the TGF-␤1-induced sensitization of TRPV1 in DRG neurons and thermal hyperalgesia in bone cancer rats (Fig. 8) .
Activation of TGF␤RI leads to the downstream propagation through Smad-dependent and Smad-independent pathways (Derynck and Zhang, 2003; Krieglstein et al., 2011) . In our study, the TGF␤1-induced enhancement of TRPV1 sensitivity occurred within 20 min and was not inhibited by the Smad3 inhibitor SIS3, indicating that the Smad-dependent signaling pathway is not involved in this rapid response. Recently, several Smadindependent pathways, including various branches of the MAP kinase (ERK, JNK, and p38) and PKC pathways, have been reported in different cell types Nagaraj and Datta, 2010) . PKC, in particular the PKC isoform, has been implicated in the sensitization of TRPV1 by NGF (Zhu and Oxford, 2007) the TGF-␤1-induced sensitization of TRPV1. In addition to PKC-mediated TRPV1 sensitization, we also found that the inhibition of TAK1, a member of the MAPKKK family (upstream of MAPK), completely blocked TGF␤1-induced TRPV1 sensitization and thermal hyperalgesia, suggesting an important role for the MAPK pathway in the cross talk between TGF␤1 and TRPV1. Utreras et al. (2012) found that TGF␤1 induced an increase in phosphor-ERK1/ERK2 in rat B104 neuroblastoma cells. In contrast, activin A did not promote phosphorylation of ERK, and inhibition of ERK failed to block the sensitization of TRPV1 by activin in cultured DRG neurons (Zhu et al., 2007) . In the present study, our data strongly implicated the activation of the TAK1-p38/MAPK pathway, but not the ERK and JNK pathways, as being critical for the TGF␤1-induced sensitization of TRPV1.
In conclusion, we have demonstrated a pivotal role for TGF-␤1-mediated intracellular signaling in thermal hyperalgesia in advanced bone cancer. The upregulation of TRPV1 expression level and sensitization of TRPV1 in nociceptors by TGF-␤ might be an important peripheral mechanism of bone cancer pain. The present study highlights the possibility of a new clinical strategy to alleviate bone cancer pain in advanced cancer.
